Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
Body unavailable. Use the original source.
Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.